The 775mg version of the drug has been developed with an extended release formulation and is a lower dose, once-daily alternative to currently approved penicillin and amoxicillin regimens for the treatment of tonsillitis and or pharyngitis.
MiddleBrook CEO John Thievon said: "Moxatag samples will be a key element of our nationwide launch to health care professional in March." Almac Pharma Services’ vice president of commercial operations, David Downey, added that the firm is happy to be working on the project.
